Opus Genetics received FDA clearance for its Investigational New Drug application of OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease causing early childhood vision loss. This clearance allows Opus to begin clinical trials, advancing a potential treatment developed in collaboration with the Global RDH12 Alliance, which supports patient advocacy and funding. The therapy aims to restore retinal function by delivering a functional RDH12 gene, addressing a high unmet medical need. Opus plans to start a Phase 1/2 trial soon, marking a significant step toward treating this devastating condition.
Opus Genetics' FDA clearance for its gene therapy IND application comes as part of a Health-sector market where 71 of 150 US stocks rose and 67 fell on Pluang. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: Baxter International Inc (BAX) traded at USD 25.30 with a 3.22% gain and a typical hold time of 73 days, Nuvation Bio Inc. Class A (NUVB) rose 2.94% to USD 4.91 with a 12-day hold, while BioNano Genomics Inc (BNGO) fell 2.81% to USD 1.21 with 100% sell order activity and a 51-day hold time.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
